TABLE 2.
Laboratory and clinical baseline parameters.
| Pat. ID | ELISA Anti-BP180 [RE/mL] | ELISA Anti-BP230 [RE/mL] | Total IgE [mU/L] | Eosinophils [absolute/relative] | BPDAI [Activity/Damage] | SCORAD | oSCORAD | Erlangen score | EASI | DLQI [x/30] | Previous therapy | Oral prednisone (initial dose) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| #1 | 55.9 | 0 | 1871 | 1.0/16.2% | A 54/D 2 | 51.51 | 34.51 | 19.5 | 17.9 | 24 | none | none |
| #2 | 1508.2 | 186.8 | 4870 | 5.29/30.9% | A 45/D7 | 65.54 | 48.54 | 15.5 | 11.2 | 12 | none | none |
| #3 | 1000.3 | 0 | 2693 | 0.21/1.5% | A38/D1 | 44.64 | 34.64 | 10.5 | 18.3 | 4 | none | 20 mg |
| #4 | 259.7 | 98.8 | 364 | 1.28/14.9% | A71/D1 | 61.85 | 46.85 | 15.5 | 23.1 | 10 | none | 50 mg |
| #5 | 1064.8 | 787.6 | 958 | 0.75/5.2% | A62/D2 | 58.41 | 47.41 | 11 | 20.7 | 11 | none | none |
| #6 | 3298.6 | 0 | 516 | 0.75/4.7% | A46/D7 | 53.87 | 41.87 | 18 | 26 | 16 | none | none |
| #7 | 71.7 | 0 | 644 | 3.5/27.2% | A31/D0 | 40.24 | 33.24 | 13 | N.A | 7 | none | none |
| #8 | 1900.7 | 1248 | 6489 | 2.73/29.7% | A61/D2 | 55.49 | 49.49 | 12.50 | 32.5 | 4 | none | 50 mg |
| #9 | 70.6 | 23.1 | 116 | 0.37/5.9% | A27/D0 | 61.9 | 24.0 | 10.5 | 24.0 | 27 | Dapson 3 months. 1 cycle IVIG | none |
| #10 | 510.4 | 0 | 306 | 0.82/6.4% | A66/D7 | 43.5 | 16.0 | 14.0 | 16.0 | 22 | none | 30 mg |
| #11 | 118.7 | 89.1 | 428 | 0.05/0.7% | A124/D11 | 46.1 | 29.8 | 11.5 | 29.8 | N.A. | Tralokinumab (3 m) | 30 mg |
| #12 | 6807.7 | 0 | 1297 | 8.71/34.1% | A49/D0 | 40.15 | 17.1 | 15.0 | 17.1 | 16 | Doxycycline (3 m); Tralokinumab (3 m) | 30 mg |
Legend: BP, Antibodies = Bullous pemphigoid-specific autoantibodies; ELISA, Anti-BP180 = Antibodies against BP180 (type XVII, collagen), measured by enzyme-linked immunosorbent assay (ELISA), in relative units per milliliter (RE/mL); ELISA, Anti-BP230 = Antibodies against BP230 (a hemidesmosomal intracellular protein), measured by ELISA, in RE/mL; Total IgE = Total immunoglobulin E levels; BPDAI [Activity/Damage] = Bullous Pemphigoid Disease Area Index, subdivided into activity and damage scores; SCORAD, scoring atopic dermatitis; Erlangen Atopy Score = Quantification of atopic diathesis based on personal and family history; EASI, eczema area and severity index; DLQI, Dermatology Life Quality Index (maximum score: 30); N.A., Not applicable due to the patient’s general condition.